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TRAIL: structure and functions 
 
Structure 
 
Tumor Necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL/Apo2L/TNFSF10) is a 
member of the TNF superfamily identified inde-
pendently by 2 teams which both reported a 
sequence homology with the extracellular do-
main of CD95 ligand (28%) (Fas-L) and of TNF 
(23%) [1, 2]. Located on chromosome 3, the 
gene that encodes the 20 kDa TRAIL protein is 
composed of five exons and four introns. Unlike 
other members of the TNF superfamily whose 
expression is often inducible and detected tran-
siently in activated cells, TRAIL mRNA was iden-
tified constitutively in most human tissues with 
an expression significantly greater in the spleen 
and prostate [2]. TRAIL, like other members of 
the TNF superfamily is expressed as a type II 
transmembrane protein composed of 281 
amino acids (aa) in the human form. Cleavage 
of its C-terminus part corresponding to the ex-
tracellular domain, releases a soluble form of 
the protein [3]. The crystal structure of the 
monomeric form of TRAIL also presents a strong 
homology with the TNF and CD40 Ligand struc-
tures (Figure 1A) [4]. TRAIL binds to its recep-
tors as a homotrimer form, this trimeric form 
being biologically much more active than the 
monomeric one (Figure 1B) [2].  
 
Functions 
 
The ability of TRAIL to induce apoptosis of trans-
formed cells has been widely demonstrated but 
its physiological role is not well defined. Mice 
deficient for the receptor or the murine form of 
TRAIL (mTRAIL) develop normally, suggesting a 
lack of role of this signaling pathway in embry-
onic development [5, 6]. TRAIL is specifically 
expressed on the surface of natural killer cells 
(NK), cytotoxic T lymphocytes, macrophages and 
dendritic cells. The transcritpion of its mRNA 
can be induced by interferon type I [7]. The se-
lective expression of TRAIL on the surface of 
effector cells of the immune system suggests a 
role of TRAIL in the formation of the immune 
repertoire and in the regulation of the immune 
response. Studies in humans and in animal 
models suggest that TRAIL plays a role in regu-
lating the immune response in order to avoid 
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excessive reactions against infectious agents 
such as cytomegalovirus or Listeria [5, 8] and 
self-antigens involved in autoimmune diseases 
such as arthritis, diabetes and multiple sclero-
sis [9-11]. Other studies suggest that TRAIL 
would have a role as tumor suppressor involved 
in immune surveillance against the develop-
ment of primary tumors or metastases. Thus, in 
mice, inhibiting the activity of TRAIL by gene 
knockout, by blocking antibodies or by inhibiting 
the mouse form of one of its death receptors 
has confirmed the role of tumor suppression in 
spontaneous or induced models of metastases 
from cutaneous lymphoma or carcinoma [12-
14]. Moreover, a recent study of 368 human 
breast tumor samples showed a correlation be-
tween a subregulation of TRAIL in these tumors 
and the presence of brain metastases [15]. If 
the role of TRAIL in inhibiting metastasis devel-
opment has been well demonstrated, its role in 
the suppression of primary tumors is still de-
bated. Thus, TRAIL-deficient mice do not de-
velop more spontaneous tumors than wild type 
mice and the development of skin tumors in 
Figure 1. structure of TRAIL. A: Surface representation of TRAIL (cyan) bounded to its cognate receptor DR5 (tube 
representation, light orange), TNF-alpha (blue), and CD40L (green). TNF-alpha and CD40L were superposed using the 
conserved anti-parallel beta-sheets scaffold to present the same orientation as DR5 (this scaffold is represented in 
ribbon representation). The variations observed in the surface rendered highlight the differences in loops shapes and 
size between ligands. Crystallographic coordinates for TRAIL, TNF-alpha and CD40L were taken from 1DU3, 1TNF and 
1ALY respectively [136-138]. The superposition was made using Discovery Studio 2.5.5 (Accelrys Inc., San Diego, 
USA) and the final rendering using POV-Ray (http://www.povray.org) and The GIMP (http://www.gimp.org). B: Ribbon 
structure of the TRAIL homotrimer (blue, yellow, pink). 
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response to chemical carcinogens is not aug-
mented [14].  
 
TRAIL receptors 
 
TRAIL is able to interact with five receptors 
(Figure 2): 2 death receptors and 3 decoy recep-
tors. It is able to bind to DR4/TRAIL-R1/
TNFRSF10A and DR5/TRAIL-R2/KILLER/
TNFRSF10B death receptors (Figure 1A) which 
can transduce a death signal, and to decoy re-
ceptors DcR1/TRAIL-R3/TNFRSF10C and 
DcR2/TRAIL -R4/TNFRSF10D which cannot [16-
18]. It has been shown that TRAIL is able of 
binding to its death receptor with a higher affin-
ity than to the decoys DcR1 and DcR2 [19]. In 
addition, TRAIL is able to bind with low affinity to 
a third soluble decoy receptor, osteoprotegerin 
(OPG/TNFRSF11B) [20]. In mice, however, 
mTRAIL can bind to only one death receptor 
mDR5 (mTRAILR2/mKILLER) that shares the 
same degree of homology with DR4 and DR5 
[21].  
DR4 and DR5 death receptors 
 
DR4 and DR5 receptors are type I transmem-
brane proteins containing in their cytoplasmic 
domain a death domain (DD) capable of binding 
to other death domains. It was long believed 
that death receptors are present at the mem-
brane in their monomeric form and trimerized 
only when interacting with their trimeric ligand. 
Now, several data indicate that these receptors 
are oligomeric already before the fixation of 
their ligand [22, 23]. The DR4 and DR5 expres-
sion may be regulated by p53 [24]. Indeed, the 
DR5 gene promoter has a responsive element 
to p53 and is overexpressed in response to γ-
irradiation through p53 [25, 26]. Post-
translational regulation of DR4 and DR5 death 
receptors such as glycosylation and palmitoyla-
tion were also shown to be important regulators 
of TRAIL induced signaling. Thus, there is a cor-
relation between the expression of the enzyme 
initiating the GALNT14 glycosylation and sensi-
tivity to TRAIL in pancreatic carcinoma cells, 
lung cancer and malignant melanoma [27]. 
However, these O-glycosylations do not appear 
to alter the expression of DR4 and DR5 to the 
membrane or their affinity for TRAIL. They seem, 
however, to affect the receptor oligomerization 
in response to TRAIL binding, this oligomeriza-
tion being necessary for the formation of the 
Death-Inducing Signaling Complex (DISC) and 
further caspase 8 activation (Figure 3). Palmi-
toylation is necessary to localize DR4 in lipid 
rafts allowing DR4 to trimerize in the absence of 
ligand, but the effect of its inhibition on the tu-
mor cell sensitivity to TRAIL has not yet been 
demonstrated [28]. The ligand binding to its 
receptors often induces endocytosis of the 
ligand-receptor complex and the role of this in-
ternalization has recently been studied in the 
case of TRAIL signaling pathway. After binding 
TRAIL, DR4 and DR5 are both internalized by a 
mechanism dependent on dynamin [29, 30]. 
The biological role of this endocytosis is cur-
rently poorly understood and its inhibition does 
not appear to influence the TRAIL induced apop-
tosis [29, 30].  
 
DcR1 and DcR2 decoy receptors 
 
The expression of these receptors has been 
shown to prevent the induction of apoptosis in 
different human tumor cell lines derived from 
lymphoma, renal, breast and prostate carci-
noma [31-33] but their involvement in TRAIL 
Figure 2. TRAIL is able to interact with five receptors: 
2 transmembrane death receptors which can trans-
duce a death signal (DR4 and DR5) and 3 decoy re-
ceptors DcR1, DcR2 and the soluble osteoprotegerin 
(OPG) which cannot.  
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resistance remains controversial [34]. About 
their modes of action, DcR1 is a receptor with a 
glycophosphatidylinositol (GPI) anchor but with 
no intracellular domains able to sequester 
TRAIL in lipid rafts. DcR2 has a truncated death 
domain and interacts with DR5 to form a het-
erotrimeric complex in the DISC to inhibit cas-
pase-8 activation [35], this interaction might 
even be upstream of the interaction with TRAIL 
[19].  
 
Osteoprotegerin (OPG) 
 
OPG was first described as a secreted member 
of the TNF receptor family (TNFRSF11B) that 
regulates bone resorption [36]. Unlike other 
members of the TNF receptor family OPG does 
not possess a transmembrane domain. Then a 
first report has provided evidence that OPG is a 
receptor for TRAIL, binding the ligand with an 
affinity of 3.0 nM and inhibiting TRAIL-mediated 
apoptosis of sensitive Jurkat cells [20].  
 
Besides these 5 cognate receptors, transcrip-
tional modifications have been identified such 
as alternative splicing in the TRAIL-R2/DR5 and 
TRAIL-R4 transcripts [37, 38]. First, two iso-
forms of DR5/TRAIL-R2, i.e. TRICK2A and 
TRICK2B which differ in the presence of a 23 aa 
extension between the transmembrane region 
and the cysteine-rich domain has been de-
scribed by Screaton and coll [37]. Then Krieg 
and coll. identified a novel alternative splice 
variant of DcR2/TRAIL-R4/TRUNDD, designated 
TRAIL-R4-β [38]. The lack of exon 3 of the 
DcR2/TRAIL-R4 gene results in truncation of the 
first complete cysteine rich domain 1 which 
seems to be essential for TRAIL-binding. 
Figure 3. TRAIL-induced apoptosis signaling pathway via the death receptors DR4 and DR5. The incoming trimeric 
ligand TRAIL recruits three receptors into a complex. The induced juxtaposition of the intracellular domains triggers 
recruitment of the intracellular signaling components forming the Death-Inducing Signaling Complex (DISC) and lead-
ing to the caspase cascade and cell death. DD: Death Domain; DED: Death Effector Domains; FADD: Fas-Associated 
protein with Death Domain; c-FLIP: cellular FLICE-inhibitory protein; BAK: B cell-CELL/Lymphoma 2 (Bcl-2) homolo-
gous Antagonist Killer; BAX: Bcl-2-Associated X; Bid: BH3-interacting domain death agonist. 
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TRAIL proapoptotic signaling pathways 
 
The binding of TRAIL to its death receptors DR4 
and DR5 induces a conformational change of 
their death domains which, along with their oli-
gomerization, is the functional activation of the 
receptor. This activation will induce the recruit-
ment of Fas-Associated protein with Death Do-
main (FADD) on the death receptors by interac-
tion of their respective death domains (Figure 
3). Acting as an adapter protein, FADD will allow 
the recruitment of procaspase-8/-10 by interac-
tion of their respective Death Effector Domains 
(DED) [39]. The multiprotein complex resulting 
from these associations is called DISC and in-
duces self-activation of initiator caspases [40]. 
In response to their activation, caspases-8 and 
10 will induce the proteolytic cleavage of the 
effector caspase-3 which, itself, will cleave 
other caspases and other regulators and struc-
tural proteins [41]. This will result in a sprouting 
of the plasma membrane, nucleus condensa-
tion and cleavage of the chromatin leading to 
cell apoptosis known as the extrinsic pathway 
(death receptor pathway) [42]. A bridge be-
tween extrinsic and intrinsic (mitochondrial) 
apoptosis pathways exists through the protein-
BH3 interacting domain death agonist (Bid), a 
member of the B cell-CELL/Lymphoma 2 (Bcl-2) 
family, a substrate for caspase 8. Depending on 
the cell type, the cleavage of Bid (p22) into tBid 
(p15) will be linked or not to the primary mecha-
nism of apoptosis induction in response to 
TRAIL [43]. The presence or absence of X-linked 
inhibitor of apoptosis protein (XIAP) and the 
negative regulation of caspase 3 activation 
might also be involved in this categorization of 
cells. The cleaved form of the Bid protein tBid, 
initiates the intrinsic pathway of apoptosis by 
binding to Bcl-2-Associated X (BAX) and Bcl-2 
homologous Antagonist Killer (BAK). This will 
result in their oligomerization and translocation 
to the outer membrane of mitochondria that 
initiates the permabilization of this membrane 
[44]. Pro-apoptotic proteins such as cytochrome 
c and Second mitochondria-derived activator of 
caspase/Direct Inhibitor of Apoptosis-Binding 
protein with Low pI (Smac/DIABLO), normally 
located in the membrane inter-space of the mi-
tochondria membrane will be released in the 
cytosol [45]. Cytochrome c associates with ATP 
and Apoptotic Peptidase Activating Factor-I 
(APAF-1) to form a structure called the apopto-
some, which will induce caspase-9 activation. In 
turn, caspase-9 will activate caspase-3, -6 and -
7 leading to cell apoptosis called the intrinsic 
pathway [46].  
 
TRAIL induced non-apoptotic signaling path-
ways 
 
Many studies have shown that TRAIL is not only 
involved in the induction of apoptosis through 
its death receptors but is also able to induce 
survival signals and cell proliferation. The nu-
clear factor kappa B (NF-kB) would be activated 
via DR4, DR5 and DcR2 receptors by the forma-
tion of a secondary signaling complex generated 
after the DISC formation [47, 48] (Figure 4). 
This complex involves FADD, activated caspase-
8, the Receptor Interacting Protein 1 (RIP1), 
TNF-Receptor Associated Protein (TRAF-2), TNF 
Receptor-Associated Death Domain (TRADD) 
and Inhibitor of kappa B kinase (IKKγ/NEMO) 
[49] (Figure 4). Thus, after recruitment, RIP will 
interact with IKKγ leading to the recruitment of 
IKKα and β, which will phosphorylate the Inhibi-
tor of kappa B (IκB) inducing its proteolytic deg-
radation and the further activation of NF-kB. 
This activation of NF-kB is able to induce cell 
survival through overexpression of various anti-
apoptotic proteins such as c-FLIP, BCL-extra 
large (BCL-Xl), Myeloid cell leukemia sequence 
1 (MCL1) and cIAPS [50, 51]. In addition, this 
complex is able to induce survival signals involv-
ing phosphoinositide 3-kinase (PI3K)-Akt and 
mitogen-activated protein kinase (MAPK: Jun-
terminal kinase (JNK), extracellular signal-
regulated kinase 2 (Erk2) and p38) [52, 53]. It 
seems that in resistant cells, the main signal 
induced by TRAIL is the one involving NF-kB. A 
study of a resistant form of cholangiocarcinoma 
to apoptosis has shown that the activation of NF
-kB may promote invasion and metastasis [54]. 
Similarly, it has been shown in a preclinical 
model of adenocarcinoma resistant to apop-
tosis induced in Severe Combined ImmunoDefi-
ciency (SCID) mice that a treatment with TRAIL 
increases the formation of metastases [50].  
 
Using TRAIL in cancer therapy 
 
Preclinical studies 
 
Over the past 10 years, TRAIL has become the 
most promising members of the TNF super-
family to be used in cancer therapy. This inter-
est arises from the ability of TRAIL to induce 
apoptosis specifically in cell lines derived from 
solid and hematological tumors in combination 
TRAIL receptor and bone tumors 
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with various chemotherapy agents or with radia-
tion in vitro but also in vivo without significant 
effects on normal cells [1, 2, 55-61]. The results 
of the specific antitumor activity of TRAIL have 
suggested that it might represent a better candi-
date for clinical use than CD95L or TNF, which 
have deleterious side effects in vivo. However, 
the use of TRAIL as a therapeutic agent in clini-
cal trials has been delayed due to in vitro stud-
ies showing apoptosis induction in hepatocyte 
cultures treated with a recombinant form of 
TRAIL (rhTRAIL) [62-64]. However, all the recom-
binant forms of TRAIL used in these studies had 
an exogenous polyhistidine tag or flag and it 
was subsequently shown that these tagged 
forms have an aberrant tertiary structure induc-
ing an over-aggregation of receptors, responsi-
ble for side effects observed in hepatocytes 
[63]. It has been shown since that a non-tagged 
recombinant form of TRAIL specifically induces 
apoptosis of tumor cells without side effects on 
hepatocytes [65]. Agonist antibodies to TRAIL 
death receptors have also been tested in sev-
eral experimental models. For example, the abil-
ity of 2 human monoclonal antibodies (mAbs) 
directed against DR4 and DR5 have been evalu-
ated to kill human myeloma cells by the cleav-
age of Myeloid cell leukemia (Mcl)-1L, a major 
molecule for myeloma survival [66]. 
 
Clinical trials (Table 1) 
 
Clinical trials were conducted to evaluate the 
antitumor potential of TRAIL for solid and hema-
tologic tumors. A phase 1 clinical trial was con-
ducted on 51 adult patients including 36 with 
colorectal, ovarian, lung and melanoma cancer 
to study the pharmacokinetics and safety of 
rhTRAIL [67]. During this test, TRAIL showed no 
toxicity and no antibody directed against 
rhTRAIL was detected. Preclinical studies having 
shown a potentiation of TRAIL effect in combina-
tion with chemotherapeutic agents [68, 69], a 
phase 1b clinical trial was conducted with a 
combination of rituximab (anti-CD20) with 
rhTRAIL on patients with non Hodgkin's low 
grade lymphoma [67]. Of 7 patients, 2 had a 
complete response, 1 a partial response and 2 
a stabilization of the disease. This study showed 
that a combination of rituximab with rhTRAIL 
had no side effects and showed a positive activ-
ity in these patients. Another clinical trial was 
conducted in patients with advanced lung can-
cer with a combination of rhTRAIL and pacli-
Figure 4. TRAIL-induced non apoptotic 
signaling pathways. The trimeric TRAIL 
can also induce recruitment of intracel-
lular components leading to activation 
of NF-kB. RIP1: Receptor Interacting 
Protein 1, TRAF2: TNF-Receptor Associ-
ated Protein, TRADD: TNF-Receptor 
Associated Death Domain, IKKγ/
NEMO: Inhibitor of ΚB Kinase, BCL-Xl: 
BCL-extra large, MCL1: Myeloid cell 
leukemia sequence 1, cIAPs: cellular 
inhibitors of apoptosis, PI3K: Phos-
phoInositide 3-Kinase-Akt, MAPK: mito-
gen-activated protein kinase, Erk2: 
extracellular signal-regulated kinase 2.  
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taxel, carboplatin and bevacizumab (anti-
vascular endothelial growth factor A). Results of 
this trial confirmed the safety of the combina-
tion of rhTRAIL with chemotherapy agents as 
well as a promising anti-tumor efficacy. The re-
sults of this clinical trial show that of 18 pa-
tients, 10 experienced a confirmed response (9 
partial and 1 complete) with a response rate of 
56%. Given these promising results, a phase 2 
clinical trial is currently underway on the same 
pathology. 
 
Because rhTRAIL hepatotoxicity, monoclonal 
antibodies agonists of its death receptors have 
been developed and used in clinical trials (Table 
1). Several phase 1 and 2 clinical trials are be-
ing or have been conducted with the antibody 
agonist of DR4, the mapatumumab on ad-
vanced solid tumors or non-Hodgkin lymphoma 
(recurrent or resistant) with or without chemo-
therapy agents such as paclitaxel plus car-
boplatin or gemcitabine plus cisplatin [70-76]. 
The mapatumumab is well tolerated showing a 
half-life of about 18 days and patients have 
shown clinical benefits with partial responses or 
stable disease. However, elevated liver markers 
were measured in some patients, probably due 
to the administration of mapatumumab.  
 
Clinical phase 1 trials were also conducted with 
DR5 agonist antibody, the lexatumumab on pa-
tients with advanced solid tumors in combina-
tion or not with a cocktail of chemotherapeutic 
agents consisting of gemcitabime, premetrexeb, 
doxorubicin and FOLFIRI (leuvovorin, 
fluorouracil and irinotecan) [77, 78]. This anti-
body is well tolerated and has a half-life of ap-
proximately 16 days. Again some patients had 
stable disease and partial responses. The apo-
mab [79], another DR5 agonist antibody is cur-
rently tested in a Phase 1 clinical trial in ad-
vanced solid tumors resistant to treatment. Half
-life was found to be 15-20 days and it is also 
well tolerated. No objective response was ob-
served but 2 patients appeared to have clinical 
benefits.  
 
Primary malignant bone tumors 
 
Osteosarcoma is the most frequent malignant 
tumor of the bone in the pediatric age group, 
with an incidence of 8.7 per million in children 
and adolescents under the age of 20 years [80]. 
Its incidence peaks during the second decade 
of life coinciding with the adolescent growth 
spurt. It is more commonly seen in the metaphy-
seal region of long bones: the disteal femur, 
proximal tibia and proximal humerus being the 
most common sites and corresponding to areas 
of active growth in the body (Figure 5A). Overall 
survival rates in nonmetastatic osteosarcoma 
were a dismal 10% prior to the 1970s when 
surgery was the only treatment option. Since the 
1980s, the use of multidrug chemotherapy and 
refined surgical techniques has dramatically 
increased to 65% the overall survival rates in 
nonmetastatic osteosarcoma [81]. The outlook 
for metastatic osteosarcoma continues to be 
grim with reported survival rates of 20% [82].  
 
Ewing’s sarcomas are the second most frequent 
malignant bone tumors arising predominantly in 
Table 1. Clinical trials using recombinant human TRAIL (rhTRAIL) or agonist antibodies (Mapatumumab, 
Lexatumumab and Apomab) of death receptors DR4 or DR5. CRC: colorectal cancer; O: ovarian; L: lung; 
M: myeloma; NHL: non-Hodgkin lymphoma; NSCLC: nonsmall cell lung cancer. 
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the bones of children and young adults, the me-
dian age at diagnosis being 14 years with most 
patients presenting between the ages of 5 and 
20 years [83]. Tumors may arise in bone or soft 
tissue, and symptoms generally include local-
ized pain and a visible or palpable mass (Figure 
5B). The femur is the most common long bone 
involved, and bones of the pelvis are the next 
most commonly involved site. Extraosseous Ew-
ing’s sarcomas comprise 15% of cases and may 
arise anywhere else in the body, including skin 
and visceral organs. Patients with Ewing’s sar-
coma who present with localized disease have a 
better prognosis than those with metastatic 
disease. The most common sites of metastasis 
are the lungs, bone and bone marrow. The Ew-
ing’s Sarcoma family of tumors (ESFT) com-
prises morphologically heterogeneous tumors 
that are characterized by nonrandom chromoso-
mal translocations involving the EWS gene and 
one of the several members of the ETS family of 
transcription factor genes [84]. The mainstay of 
therapy for Ewing’s sarcoma includes a combi-
nation of systemic chemotherapy and local con-
trol with surgery and/or radiation therapy [85]. 
 
Chondrosarcomas are the second most com-
mon primary bone sarcoma in adults after os-
teosarcoma. Conventional chondrosarcomas 
are characterized by the synthesis of pure hya-
line cartilage by malignant cells [86]. Unlike 
osteosarcoma, chondrosarcoma is extremely 
unusual in the first two decades of life and tend 
to affect axial skeleton.  
 
Altogether, the primary bone cancers, Ewing’s 
sarcoma, osteosarcoma and chondrosarcoma 
account for 4/5 primary bone sarcomas [87]. 
These malignancies require not only adequate 
local control measures (i.e. surgery or radiother-
apy) but also systemic therapy to reduce the 
high probability of lung and/or bone metastases 
(Figure 6). The improvement in survival ob-
served in the mid 1980’s has been attributed to 
Figure 5. Radiographies of osteosarcoma (A) and 
Ewing’s sarcoma (B). Ill defined osteolytic lesion in-
volving metaphysis (osteosarcoma) or diaphysis 
(Ewing’s sarcoma) of long bone is the most common 
feature. The underlying cortex is commonly partially 
destroyed, and periosteal new bone is commonly 
present at the periphery of the tumor. Characteristic 
permeative bone destruction is often associated with 
"onion-skin" or “sunburst” periosteal reaction. In Ew-
ing’s sarcoma, a large ill-defined soft tissue mass is 
frequently seen. In addition, expansile bone destruc-
tion with soap-bubble appearance might be seen. 
Figure 6. Current osteosarcoma and Ewing’s sarcoma local and systemic treatment. Approximately 10-16 weeks of 
preadjuvant therapy is given to patients before local control measures (surgery and/or radiation for Ewing’s sarcoma) 
in an effort to control micrometastases. In osteosarcoma, the choice of adjuvant chemotherapy is influenced by the 
chemotherapy response. At the end of the standard treatment therapy, high-risk subsets with lung metastases get 
local control . 
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the use of intensive multidrug chemotherapy 
given in combination with advanced surgery. 
However, since then no substantial further im-
provement of survival is observed [88, 89]. De-
spite survival about 65-75% in non metastatic 
Ewing’s Sarcoma and Osteosarcoma, there re-
mains much room for improvement in therapy. 
This would include regimens with fewer short- 
and long-term side effects and better results for 
difficult locations and patients with recurrent 
disease.  
 
Because Ewing’s sarcoma and osteosarcoma 
tend to occur during periods of rapid bone 
growth, i.e. adolescents and young adults, and 
because of pleiotropic effects of insulin-like 
Growth Factor (IGF)-1R signaling on cancer cell 
proliferation and survival pathways, these tar-
geted agents have been of great interest in Ew-
ing’s sarcoma and osteosarcoma [90]. The 
status of other investigational agents for OS 
includes liposomal muramyltripeptide phos-
phatidylethanolamine (L-MTP-PE), aerosol thera-
pies including granulocyte-macrophage colony 
stimulating factor (GM-CSF), cisplatin and gem-
citabine, and bone-specific approaches. Indeed, 
recent favorable experience in a benign bone 
tumor (giant cell tumor of bone) with the anti-
RANKL (receptor activator of NF-kB Ligand) anti-
body denosumab® shows that agents that mod-
ify bone physiology may provide potential bene-
fit for patients with bone tumors [91].  
 
Therefore, considering the lack of improvement 
in overall survival rates for both Ewing’s sar-
coma and osteosarcoma since three decades 
and the potential therapeutic impact of TRAIL in 
several cancers, the use of this agent or the 
agonist antibodies to its death receptors may 
provide promising therapeutic value in such 
bone tumors. 
 
TRAIL and bone tumors 
 
Many experimental studies of the application of 
TRAIL to osteosarcoma cells have been reported 
[92, 93]. However, treatment of osteosarcoma 
cells with TRAIL did not lead to satisfactory re-
sults, since sensitivity of osteosarcoma cells to 
TRAIL-induced apoptosis is lower than that of 
other types of tumor cells. Indeed, cell sensitiv-
ity to TRAIL is different in various cells and the 
lack of sensitivity in osteosarcoma cells remain 
unclear [94]. Therefore, additional agents to 
sensitize osteosarcoma cells to TRAIL-induced 
apoptosis have been proposed but the problem 
of side-effects still remains [95, 96].  
 
In contrast, TRAIL can induce caspase-
dependent apoptosis in the majority of Ewing's 
sarcoma cell lines studied thus showing the 
importance of this therapeutic approach [97-
99]. Ewing’s sarcoma cell lines have been iden-
tified as highly sensitive to TRAIL in vitro, espe-
cially in cells that express TRAIL receptors [97-
100]. In patient biopsies, a study showed that 
80% of Ewing's tumor samples express DR4 and 
that all of them express DR5 [100]. Another 
study performed with 32 samples of Ewing's 
sarcoma has shown that 72% express both DR4 
and DR5 receptors, 25% one of them, and 3% 
of these samples express none of the two death 
receptors [98]. These results suggest a high 
probability of sensitivity of Ewing's sarcoma to 
TRAIL-induced apoptosis and justify the use of 
such treatment by activating this apoptosis 
pathway.  
 
In vivo, few groups studied the therapeutic ef-
fect of TRAIL and DR5 agonist in xenograft mod-
els of Ewing's sarcoma [101, 102]. The results 
were very encouraging in ES models induced by 
sensitive cell lines, showing a 87% inhibition of 
primary bone tumor incidence and growth, and 
the prevention of tumor-induced osteolysis, 
leading to a significant 2-fold increase in animal 
survival 40 days after tumor induction. Further-
more, TRAIL inhibited tumor nodule dissemina-
tion in lungs and increased survival in an os-
teosarcoma model [101]. 
 
Currently, no clinical trial using TRAIL or DR4/
DR5 agonist antibodies is underway in primary 
bone tumors. However, the major limitation of 
clinical use of TRAIL or DR4/DR5 agonists is the 
appearance of resistance phenomena. How-
ever, some cell lines resistant to conventional 
chemotherapy agents such as adriamycin or 
etoposide, are sensitive to TRAIL, demonstrating 
the interest of TRAIL for an alternative treat-
ment for these patients whose survival rate at 5 
years is very low. These chemotherapy agents 
were even able to sensitize tumor cells to TRAIL-
induced apoptosis in lung carcinoma cell lines 
[103].  
 
Combination TRAIL-chemotherapy 
 
Chemotherapeutic agents such as doxorubicin 
(Dox) administered in combination with TRAIL 
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have a synergistic effect in some cancers such 
as colorectal cancer even in a cell line rendered 
resistant to TRAIL [104]. TRAIL activates primar-
ily the extrinsic pathway of apoptosis and Dox 
the intrinsic pathway which may explain a syner-
gistic effect of these two molecules [105]. Fur-
thermore, Dox can increase the pro-apoptotic 
potential of TRAIL in a preclinical model of pros-
tate cancer by inhibiting the expression of c-
FLIP, the key inhibitor of the extrinsic apoptosis 
pathway [106]. Concerning Ewing's sarcoma, 
TRAIL may also have a synergistic effect in vitro 
with bortezomib, an inhibitor of the proteasome 
used in multiple myeloma and lymphoma [107]. 
Concerning bone tumors, a study investigated 
the efficacy of TRAIL as a single agent and in 
combination with clinically relevant chemothera-
peutic drugs in fresh isolates of primary malig-
nant cells obtained from biopsy material [93]. 
The data demonstrated that chemotherapeutic 
agents were moderately effective alone and 
TRAIL alone had little or no effect in cells in cul-
ture. However, the combination of both pro-
duced a significant increase in tumor cell death, 
with doxorubicin and TRAIL providing the most 
effective combination [93]. These results also 
demonstrate the benefit of using TRAIL in can-
cer therapy in combination with chemotherapy 
agents, which can result in a synergistic effect 
or counteract the resistance of tumor cells to 
TRAIL, a major problem for its clinical use.  
 
Limits of using TRAIL in therapy: resistance 
mechanisms to TRAIL 
 
Despite the great interest of TRAIL for its ability 
to specifically induce apoptosis of tumor cells, 
many malignancies are resistant. Many resis-
tance mechanisms developed by cancer cells 
have already been described in the signaling 
pathway of TRAIL (Figure 7) and understanding 
these mechanisms is necessary to consider a 
Figure 7. Resistance mechanisms in the TRAIL signaling pathway. Numerous resistance mechanisms developed by 
cancer cells have been described at different levels of the intrinsic and extrinsic TRAIL signaling pathways. DcRs: 
Decoy Receptors, DD: Death Domain, DED: Death Effector Domains, FADD: Fas-Associated protein with Death Do-
main, c-FLIP: cellular FLICE-inhibitory Protein, Bid: BH3-interacting domain death agonist, BCL-Xl: BCL-extra large, 
MCL1: Myeloid cell leukemia sequence 1, IAPs: inhibitors of apoptosis. 
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therapeutic use of TRAIL or its death receptor 
agonists. Thus, if TRAIL is to be used as part of 
the therapeutic arsenal for Ewing’s sarcoma 
and osteosarcoma, there is a need to identify 
means of sensitizing these tumors to the effects 
of TRAIL to address local and metastatic dis-
ease. 
 
The first control point is located at the mem-
brane with TRAIL receptors, the interaction with 
death receptors being required for signal trans-
duction leading to apoptosis of tumor cells. 
Thus, a lack of DR4 at the membrane was corre-
lated with the resistance phenomena in ovarian 
cancer and a decreased location at the mem-
brane due to a lack of transport has been 
shown to amplify the resistance in colon cancer 
[108, 109]. However, the activating receptors 
are not the only ones to play a role in these re-
sistance phenomena. Thus, some tumors such 
as meningioma and medulloblastoma have a 
high rate of membrane DR4 and DR5 but are 
resistant to TRAIL [110]. 
 
Concerning Ewing’s sarcoma, sensitization of 
death receptor-induced apoptosis and abroga-
tion of TRAIL resistance in vitro lead to in-
creased tumor cell sensitivity to TRAIL and the 
concomitant inhibition of Ewing’s sarcoma 
growth [111]. According to previous studies, 
resistance to TRAIL in Ewing's sarcoma may not 
be due to the expression of activating or decoy 
receptors, the rate of DR4 and DR5 being rela-
tively constant between sensitive and resistant 
cell strains, and the decoy receptors hardly de-
tectable in these lines (sensitive or resistant). 
For example, TRAIL as a single agent induces 
apoptosis in 7 out of 9 Ewing’s sarcoma cell 
lines [100]. No difference in the surface TRAIL-
receptors was observed between sensitive and 
resistant cell lines. Pre-incubation with inter-
feron-gamma (IFN-γ) rendered the 2 resistant 
cell lines sensitive by inducing caspase-8 activa-
tion [100]. Other studies from the same group 
confirmed the relevance of using IFN-γ to en-
hance caspase-8 activation, thereby sensitizing 
resistant cell lines to TRAIL [99, 112]. The use 
of fenretinide in Ewing’s sarcomas was shown 
to upregulate cell surface expression of TRAIL 
death receptors in an ASK1- and p38-
dependent manner [113]. The correlation be-
tween death receptor expression and TRAIL sen-
sitivity is controversial depending on the stud-
ies. For example, a study from Mitsiades and 
coll describes that 9 of 10 Ewing’s sarcoma 
family tumors underwent apoptosis with TRAIL 
through activation of caspase-10, caspase-8 
(FLICE), caspase-3 and caspase-9 [98]. These 9 
cell lines express both DR4 and DR5 while the 
resistant line expressed only DR4. The resis-
tance of the cell line was overcome by restora-
tion of DR5 levels by transfection. In addition, 
levels of DcR1, DcR2 or levels of FLICE-
inhibitory protein (FLIP) did not correlate with 
TRAIL resistance. However, in our recent study a 
correlation between DR4 expression and TRAIL 
sensitivity was observed in 7 human Ewing’s 
sarcoma cell lines [101]. These discrepancies 
may rely to the cell lines studied, their culture 
conditions or TRAIL concentrations used.  
 
Several other therapeutic combinations target-
ing different steps of the TRAIL induced 
proapoptotic pathway have been proposed to 
sensitize resistant cells to TRAIL. Concerning 
osteosarcoma, a recent study determines the 
effects of bisphosphonates (BPs) which are very 
effective drugs in the treatment of bone dis-
eases, on TRAIL-resistant MG-63 human os-
teosarcoma cells [114]. These cells showed no 
response to TRAIL alone; however, pre-
treatment with BPs significantly increased TRAIL
-mediated apoptosis and cellular activation of 
caspase-3, by inducing DR5 mRNA expression 
and protein. Moreover, it has been previously 
demonstrated that MG-63 osteosarcoma cells 
are heterozygous for a dominant-negative muta-
tion in the death domain of DR4 which can con-
fer TRAIL resistance [115]. Another study from 
Takeda and coll. demonstrated that LKB1, a 
serine/threonine kinase expressed in bone and 
soft tissue sarcoma cells, associates with Death 
Associated Protein 3 (DAP3), which plays a criti-
cal role in TRAIL-mediated apoptosis through 
activation of pro-caspase 8 [116]. These au-
thors showed that co-expression of LKB1 with 
DAP3 strongly induced apoptosis in osteosar-
coma cells. 
 
More data are available from studies performed 
in Ewing’s Sarcoma Family of Tumors (ESFT). 
Several studies revealed that TRAIL resistance 
can be also overcome by proteasome inhibitors 
[97, 107]. In a first study, the cytotoxic respon-
siveness of 40 cell lines derived from represen-
tatives of the ESFT including 26 Ewing’s sar-
coma cell lines was investigated [97]. Cell death 
was induced by TRAIL incubation in more than 
60% of these cell lines. Inhibitors of macromole-
cule synthesis (actinomycin D, cycloheximide) 
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augmented susceptibility to TRAIL in TRAIL-
responsive cell lines, while these agents did not 
render TRAIL-resistant cell lines susceptible to 
TRAIL. However, the proteasome inhibitor 
MG132 sensitized these cell lines to TRAIL. An-
other more recent study confirm these results 
showing that bortezomib, a novel proteasome 
inhibitor, exhibited synergistic activity against 
two Ewing’s sarcoma cell lines when combined 
with TRAIL [107]. Another therapeutic combina-
tion to overcome TRAIL resistance was demon-
strated by Wang and coll. who have shown that 
Platelet-Derived Growth Factor (PDGF)R-β block-
ade by using Gleevec combined with TRAIL re-
sulted in antihuman Ewing’s sarcoma activity in 
vitro and in vivo, suggesting the possibility that 
combining these treatments will improve anti-
Ewing’s sarcoma therapy [117]. The effects of 
histone deacetylase inhibitors (HDI) have been 
also studied alone or in combination with TRAIL 
in EFST [118]. The authors showed that HDIs 
cooperated with TRAIL in inducing cell death in 
Ewing’s Sarcoma cell lines, but HDI-induced 
cytotoxicity does not depend on the death re-
ceptor pathway.  
 
OPG and TRAIL interplay in tumor cell biology 
 
OPG, a soluble member of the TNF receptor su-
perfamily not only plays a role in bone metabo-
lism as an inhibitor of osteoclastogenesis by its 
interaction to the cytokine RANKL, but also in 
tumor cell survival as a ligand for TRAIL. 
 
OPG transgenic mice were born with high bone 
mass associated with a marked decrease in the 
number and activity of osteoclasts [36]. OPG 
comprises 401 aa of which 21 form a signal 
peptide that is cleaved generating mature form 
of 380 aa. At the N terminus, there are four do-
mains which have cysteine-rich TNF receptor 
homologous motifs and are necessary and suffi-
cient for binding to its major target RANKL, 
therefore inhibiting osteoclastic differentiation 
and activity both in vitro and in vivo [119]. OPG, 
by efficiently binding RANKL and TRAIL, pre-
vents their association with their transmem-
brane receptors and therefore counteracts both 
the RANKL-mediated osteoclastogenesis as well 
as the pro-apoptotic activity of TRAIL [120]. 
Therefore, OPG may be involved in survival of a 
number of tumor cell types via this mechanism 
[121-123].This could be of particular impor-
tance regarding the ability of tumor cells to 
evade cell death, since host immune cells pre-
sent in the tumor microenvironment produce 
TRAIL [7, 124, 125]. As such, release of OPG by 
tumor cells is a potential mechanism of resis-
tance by these cells to TRAIL-induced apoptosis 
[121]. The biological importance of OPG-TRAIL 
interactions is underscored by recent findings 
that at physiological conditions, OPG can bind 
TRAIL with an affinity similar to that of RANKL 
[126]. In terms of tumor cell survival, in vitro 
expression studies have demonstrated both 
breast and prostate cancer cell lines to produce 
sufficient OPG to protect them against TRAIL-
induced apoptosis [121, 127]. Taking this into 
account, additional studies have been per-
formed using bone marrow stromal cells 
(BMSCs) derived from either breast or prostate 
cancer patients. In both cancer types, BMSCs 
were found to produce sufficient levels of OPG 
to protect tumor cells from TRAIL-induced apop-
tosis. This suggests that bone-derived OPG may 
be involved in promoting survival of these tumor 
cell types within the bone microenvironment 
[122, 128]. Similarly, both BMSCs and MG-63 
osteosarcoma cells have been demonstrated to 
produce OPG that can inhibit apoptosis of hu-
man myeloma cells [123]. The observation that 
OPG can inhibit TRAIL-induced apoptosis of mul-
tiple myeloma cells suggests there is a fine bal-
ance involved between the beneficial effects of 
OPG in cancer-induced bone disease and poten-
tial detrimental effects of inhibiting TRAIL-
mediated tumor cell apoptosis. Taking this into 
account, an OPG peptidomimetic OP3-4 has 
been developed [129]. Treatment of murine 
blood mononuclear cells with OP3-4 inhibited 
osteoclast formation by these cells and, unlike 
OPG, did not inhibit TRAIL-induced apoptosis of 
multiple myeloma cells [129]. In addition, it has 
been shown that multiple myeloma cells inhibit 
OPG release by stromal cells, thereby promoting 
osteoclast activation and lytic bone disease (by 
enhancing RANKL availability) while at the same 
time exposing themselves to higher levels of 
ambient TRAIL [130]. Thus, as a recurring 
theme, the relative levels of pro- versus anti-
apoptotic molecules that act in a cell autono-
mous manner or in the milieu of the bone mar-
row microenvironment determine the outcome 
of potentially lethal signals. 
 
The majority of in vivo models indicate that OPG 
can decrease bone lysis associated with cancer-
induced bone disease, leading indirectly to a 
reduction in tumor growth due to space limita-
tions and possibly inhibition of bone-derived 
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growth factor release. Concerning osteosar-
coma, Lamoureux and coll. have previously 
demonstrated that OPG administered by gene 
transfer was effective in preventing the forma-
tion of osteolytic lesions associated with tumor 
development in a preclinical model of osteosar-
coma, in reducing tumor incidence and the local 
tumor growth, leading to a 4-fold augmentation 
of mice survival 28 days postimplantation 
[131]. Because OPG has no direct activity on 
osteosarcoma cells in vitro (cell binding, cell 
proliferation, apoptosis, or cell cycle distribu-
tion), the authors suggest that OPG exerts indi-
rect inhibitory effect on tumor progression 
through the inhibition of RANKL whose produc-
tion is enhanced in bone tumor environment. In 
addition, no pro-tumoral effect through TRAIL 
inhibition could be observed in these condi-
tions. However, employing a new assay system 
for the TRAIL-OPG complex, Mogi and Kondo 
recently demonstrated that this complex is con-
stitutively present in the human osteosarcoma 
cell lines HOS and MG-63 [132]. 
 
The role of OPG in vivo seems therefore to be 
dependent upon the relative concentrations, 
timing and location of OPG, TRAIL and their 
ligands, particularly in the local bone marrow 
environment. The extent of crosstalk between 
tumor cells and the surrounding stroma will also 
influence the expression levels of the molecules 
involved in the OPG/RANKL system, both in the 
primary tumor and in bone metastases [133]. 
As OPG is abundantly released by cells from the 
tumor and normal microenvironment including 
MSC, fibroblasts and endothelial cells, a recent 
study investigated the effect of TRAIL on OPG 
release [134]. Unexpectedly, recombinant TRAIL 
decreased the spontaneous OPG release in all 
cell types examined through decreased of the 
phosphorylation levels of p38/MAPK, suggest-
ing that this pathway is involved in the stabiliza-
tion of OPG mRNA.  
 
This interplay is even more complex when con-
sidering the study of Nicolin and Narducci 
[135]. The authors have shown that the breast 
cancer cell line MDA-MB-231 produces a suffi-
cient amount of OPG to bind TRAIL, resulting in 
an upregulation of RANKL mRNA expression. 
The authors conclude that the presence of OPG 
as secreted by this cell line and acting as a 
paracrine factor could affect breast cancer 
RANKL production inducing an enhancement of 
osteolysis and the perpetuation of a vicious cy-
cle. 
Conclusion 
 
Several years of intensive research have proved 
that TRAIL could play a major role in cancer 
therapy, as a single agent or combined with 
chemotherapy by overcoming the drug resis-
tance in specific cancers. However, the story of 
TRAIL and its receptors is very complex with 
conflicting results, reflecting the interplay be-
tween several receptors, possible redundancy 
and differing expression and sensitivity between 
tissues. For example, TRAIL resistance remains 
a crucial limit for its clinical use, especially in 
osteosarcoma which are poorly sensitive to 
TRAIL. The better knowledge of TRAIL receptors 
and signaling pathways has allowed a better 
management of TRAIL resistance, by its combi-
nation with several drugs able to resensitize 
cancer cells to TRAIL. Concerning bone tumors, 
another level of regulation is added by the pres-
ence and production by bone cells and MSC of 
OPG which is able to interact with TRAIL. There-
fore, complementary studies are needed to bet-
ter understand the complex tumor cell-host cell 
interactions in the bone microenvironment and 
of autocrine and paracrine effects of the se-
creted (from tumor cells) and released (from 
bone matrix) factors which may facilitate the 
development of effective TRAIL strategies to 
inhibit disease progression.  
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